| scholarly article | Q13442814 |
| P50 | author | Mariusz Papp | Q59505989 |
| Magdalena Lasoń-Tyburkiewicz | Q114739568 | ||
| Piotr Gruca | Q59505987 | ||
| P2093 | author name string | István Gyertyán | |
| Béla Kiss | |||
| Nika Adham | |||
| P433 | issue | 5-6 | |
| P921 | main subject | anhedonia | Q545365 |
| cariprazine | Q2938837 | ||
| P304 | page(s) | 567-574 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Behavioural Pharmacology | Q15754239 |
| P1476 | title | Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression | |
| P478 | volume | 25 |
| Q64954388 | Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. |
| Q42141320 | Cariprazine Exhibits Anxiolytic and Dopamine D3 Receptor-Dependent Antidepressant Effects in the Chronic Stress Model |
| Q89941165 | Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data |
| Q28071940 | Cariprazine for Schizophrenia and Bipolar Disorder |
| Q57483192 | Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy |
| Q36530048 | Cariprazine in the treatment of schizophrenia: a proof-of-concept trial |
| Q46587577 | Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial |
| Q36473504 | Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) |
| Q91646537 | Corticosterone Injection Impairs Follicular Development, Ovulation and Steroidogenesis Capacity in Mice Ovary |
| Q41310518 | Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment`. |
| Q59128324 | Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial |
| Q89714970 | Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial |
| Q58786918 | Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP) |
| Q39036691 | Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine |
| Q39233330 | Managing Negative Symptoms of Schizophrenia: How Far Have We Come? |
| Q90397234 | Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine |
| Q49387505 | Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients |
| Q64910983 | The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity. |
| Q90210091 | The role of dopamine D3 receptors in the mechanism of action of cariprazine |
| Q26741533 | Update on schizophrenia and bipolar disorder: focus on cariprazine |
Search more.